Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Elan Maxipime Shortage Due To Manufacturing Suspension

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Maxipime manufacturer Bristol-Myers Squibb says it temporarily stopped manufacturing cefepime in January due to documentation issues related to bulk manufacturing. FDA accepts Bristol request to release additional product under an amended filing April 12, Bristol says.

You may also be interested in...



Prialt Sales Sluggish, But Elan Expects Rapid Growth

Additional audiences for the pain product are being targeted following a "quiet" launch at the beginning of the year.

NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter

DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Table

View full table

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

PS061967

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By